Emma Barber
Gynecologic Oncology · Chicago, ILNPI 1346551561
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,800 of the $6,735 with a category attached, or 86.1%. 9 manufacturers reported payments, led by Merck at 46.1% of the total. Reporting peaked in 2023 at $2,931 and has fallen 82.2% since, to $522 in 2025.
Across 24 payments — averaging $280.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- GSK$3K
- AbbVie$144
- AstraZeneca$132
- Intuitive Surgical$127
- Foundation Medicine, Inc.$113
- plus $214 from 3 others
Across 12 payments — averaging $74,210 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$671K
- Merck$220K
What the payments were for
- Consulting fees$5,80086%
- Food & beverage$93514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $3,102 |
| GSK | 4 | $2,902 |
| AbbVie | 1 | $144 |
| AstraZeneca | 4 | $132 |
| Intuitive Surgical | 1 | $127 |
| Foundation Medicine, Inc. | 4 | $113 |
| Baxter Healthcare | 1 | $106 |
| On Target Laboratories, Inc | 1 | $97 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$3,000
- ZEJULA$2,800
- Elahere$144
- Da Vinci Surgical System$127
- FLOSEAL$106
How this compares
$6,735 in reported general payments places this provider in the 75th percentile of 64 gynecologic oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 13 | $105 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Chicago
- Amina AhmedChicago$1.1M
- Dario RoqueChicago$587K
- Jenna MarcusChicago$230K
- Emily HinchcliffChicago$62K
- Summer DewdneyChicago$59K
- Kathryn MillsChicago$32K
- Wilberto Nieves-NeiraChicago$23K
- Amy AlexanderChicago$22K
- Freidoon AziziChicago$14K
- John MoroneyChicago$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.